DNAJC5 and malaria: Phase III trial results demonstrated that vaccination with RTS,S, which contains portions of the central repeat domain and C terminal T cell epitopes of Plasmodium falciparum CSP (PfCSP) scaffolded to the Hepatitis B virus surface antigen (HBsAg), induced a reduction in malaria cases in children over a span of 5 years4,9–11.